Trends in COVID-19 Outcomes in Kidney Transplant Recipients During the Period of Omicron Variant Predominance

作者：Florentino Villanego, Luis Alberto Vigara, Marta Alonso, Cristhian Orellana, Ana María Gómez, Myriam Eady, María Gabriela Sánchez, Rosa Gómez, Teresa Gómez García, Auxiliadora Mazuecos · 发表于：Transplantation · 年份：2022 · DOI：10.1097/tp.0000000000004126 · 被引用次数：22 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、SARS-CoV-2 detection and testing

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has spread rapidly worldwide.1 In Spain, it became predominant as of December 2021. Greater transmissibility and less severity have been described in the general population.2 However, no data have been reported on kidney transplant (KT) patients during the Omicron-predominant period. In addition, KT recipients have received a third dose of the mRNA vaccine after its approval in Spain in September 2021. We performed a multicenter retrospective cohort study to analyze coronavirus disease-19 outcomes among our KT population throughout 2 successive epidemic waves in a period with changes in the viral variants and in the vaccination schedule: Spanish fifth wave (June–November 2021; Delta predominance, n = 27) and sixth wave (December 2021–February 2022; Omicron predominance, n = 117). The incidence of SARS-CoV-2 infection in our cohort of KT patients was 4.3-fold higher during the last sixth wave (Table 1). The percentage of vaccination was very high and similar in both periods, but as expected, more patients had received a third dose in the last wave (11.5% versus 93.8%; P < 0.001). Fortunately, clinical picture has changed with less presence of fever and prevailing upper respiratory tract symptoms. There is a trend to a lower pneumonia and hospitalization incidence but without statistical differences. Additionally, critical patients, defined by intensive care unit admissions (22.2% versus 2.6%; P < 0.00...